BioSpace News Archive

Alebund Pharmaceuticals (“Alebund” or the “Company”) announced phase II proof-of-concept study results for the investigational drug, AP306, a first-in-class, pan-inhibitor of sodium-dependent phosphate transporters, which was discovered by Chugai Pharmaceutical Co., Ltd., and previously referred by EOS789.

BioVaxys Technology Corp. announced today that it is in non-binding discussions to acquire an immunotherapeutics intellectual property portfolio of discovery, preclinical and clinical development stage assets in oncology and other immunological fields formerly owned by an unnamed biotechnology company and now held by the secured creditor.

Delix Therapeutics today announced it has been awarded a $320,000 grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to support the advancement of DLX-007.

Coya Therapeutics, Inc. today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman.

An international team started the research project CERTAINTY in December 2023. Together with partners from science, industry and the healthcare sector, the project team led by the Fraunhofer Institute for Cell Therapy and Immunology IZI aims to develop a virtual twin that will improve treatment with personalized cancer immunotherapies in the future.

iECURE, Inc. announced today that the Australian Therapeutic Goods Administration (TGA) has approved the Company’s Clinical Trial Notification (CTN) for ECUR-506 (formerly GTP-506), an investigational therapy in development for the treatment of Ornithine Transcarbamylase (OTC) deficiency in pediatric (or neonatal) patients.

Vergent Bioscience announced that the company has enrolled the first patients in a Phase 2, multi-center study evaluating the efficacy and safety of VGT-309 in patients with cancer in the lung.

AltPep Corporation today announced that Soon Hyouk Lee has assumed the position of Chief Business Officer of AltPep.

Precision BioSciences, Inc. today announced that its partner iECURE has received approval from the Australian Therapeutic Goods Administration for the initiation of a first-in-human Phase 1/2 trial evaluating ECUR-506, incorporating an ARCUS nuclease for the treatment of Ornithine Transcarbamylase (OTC) deficiency in pediatric (or neonatal) patients.

RenovoRx, Inc. announced today that the Company has filed an international patent application under the Patent Cooperation Treaty (PCT) for its novel Trans-Arterial Micro-Perfusion (TAMP) therapy platform.